Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China.
Pingyu ChenMengjie LuoYanqiu ChenYanlei ZhangChao WangHongchao LiPublished in: Health economics review (2024)
Edaravone dexborneol is a cost-effective treatment choice for acute ischemic stroke patients compared with human urinary kallidinogenase in China.